Join
Live feed
·
PRReleasevia Quantisnow
Incyte Corp. logo

Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

ByQuantisnow·Wall Street's wire, on your screen.
INCY· Incyte Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INCY (Incyte Corp.) and more on Quantisnow.